Alpha Tau Medical Valuation
Is DRTS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of DRTS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate DRTS's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate DRTS's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DRTS?
Key metric: As DRTS is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is DRTS's PB Ratio? | |
|---|---|
| PB Ratio | 2.3x |
| Book | US$69.40m |
| Market Cap | US$160.48m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -3.1x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does DRTS's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 7.8x | ||
NVRO Nevro | 0.6x | 3.4% | US$163.4m |
PDEX Pro-Dex | 4.9x | 18.2% | US$138.0m |
MYO Myomo | 16.6x | 71.6% | US$145.2m |
KRMD KORU Medical Systems | 9.1x | 62.2% | US$164.2m |
DRTS Alpha Tau Medical | 2.3x | n/a | US$160.5m |
Price-To-Book vs Peers: DRTS is good value based on its Price-To-Book Ratio (2.3x) compared to the peer average (7.8x).
Price to Book Ratio vs Industry
How does DRTS's PB Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Book vs Industry: DRTS is good value based on its Price-To-Book Ratio (2.3x) compared to the US Medical Equipment industry average (2.5x).
Price to Book Ratio vs Fair Ratio
What is DRTS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 2.3x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate DRTS's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$2.32 | US$8.75 +277.2% | 32.7% | US$13.00 | US$5.00 | n/a | 4 |
| Nov ’25 | US$2.30 | US$9.25 +302.2% | 24.6% | US$13.00 | US$7.00 | n/a | 4 |
| Oct ’25 | US$2.32 | US$9.25 +298.7% | 24.6% | US$13.00 | US$7.00 | n/a | 4 |
| Sep ’25 | US$2.45 | US$9.25 +277.6% | 24.6% | US$13.00 | US$7.00 | n/a | 4 |
| Aug ’25 | US$2.08 | US$9.25 +344.7% | 24.6% | US$13.00 | US$7.00 | n/a | 4 |
| Jul ’25 | US$2.55 | US$9.25 +262.7% | 24.6% | US$13.00 | US$7.00 | n/a | 4 |
| Jun ’25 | US$2.51 | US$9.25 +268.5% | 24.6% | US$13.00 | US$7.00 | n/a | 4 |
| May ’25 | US$2.43 | US$9.25 +280.7% | 24.6% | US$13.00 | US$7.00 | n/a | 4 |
| Apr ’25 | US$2.90 | US$9.25 +219.0% | 24.6% | US$13.00 | US$7.00 | n/a | 4 |
| Mar ’25 | US$3.00 | US$10.75 +258.3% | 39.1% | US$18.00 | US$8.00 | n/a | 4 |
| Feb ’25 | US$3.28 | US$10.75 +227.8% | 39.1% | US$18.00 | US$8.00 | n/a | 4 |
| Jan ’25 | US$3.01 | US$10.75 +257.1% | 39.1% | US$18.00 | US$8.00 | n/a | 4 |
| Dec ’24 | US$3.16 | US$11.67 +269.2% | 38.5% | US$18.00 | US$8.00 | n/a | 3 |
| Nov ’24 | US$3.42 | US$13.00 +280.1% | 28.8% | US$18.00 | US$9.00 | US$2.30 | 3 |
| Oct ’24 | US$3.79 | US$15.50 +309.0% | 34.9% | US$23.00 | US$9.00 | US$2.32 | 4 |
| Sep ’24 | US$3.59 | US$15.50 +331.8% | 34.9% | US$23.00 | US$9.00 | US$2.45 | 4 |
| Aug ’24 | US$3.88 | US$15.50 +299.5% | 34.9% | US$23.00 | US$9.00 | US$2.08 | 4 |
| Jul ’24 | US$4.37 | US$15.00 +243.2% | 32.9% | US$23.00 | US$9.00 | US$2.55 | 5 |
| Jun ’24 | US$4.19 | US$15.00 +257.8% | 32.9% | US$23.00 | US$9.00 | US$2.51 | 5 |
| May ’24 | US$3.06 | US$15.00 +391.0% | 32.9% | US$23.00 | US$9.00 | US$2.43 | 5 |
| Apr ’24 | US$2.87 | US$17.25 +501.0% | 23.0% | US$23.00 | US$12.00 | US$2.90 | 4 |
| Mar ’24 | US$3.39 | US$17.25 +408.8% | 23.0% | US$23.00 | US$12.00 | US$3.00 | 4 |
| Feb ’24 | US$3.78 | US$17.25 +356.3% | 23.0% | US$23.00 | US$12.00 | US$3.28 | 4 |
| Jan ’24 | US$3.18 | US$17.25 +442.5% | 23.0% | US$23.00 | US$12.00 | US$3.01 | 4 |
| Dec ’23 | US$4.06 | US$17.25 +324.9% | 23.0% | US$23.00 | US$12.00 | US$3.16 | 4 |
| Nov ’23 | US$4.40 | US$19.00 +331.8% | 3.7% | US$20.00 | US$18.00 | US$3.42 | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Elevance Health
US$93.6b
Operates as a health benefits company in the United States.
ELV
US$402.55
7D
0.5%
1Y
-15.9%
Lantheus Holdings
US$6.1b
Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
LNTH
US$90.52
7D
17.8%
1Y
31.5%
electroCore
US$64.0m
A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.
ECOR
US$11.21
7D
2.5%
1Y
101.6%